Skip to content
OpenCapital
Get started

Harrow HROW Compounding — Research And Development Expense

Other segment segments

Branded
$5.62M+182%

Similar metrics at other companies

The Cooper Companies, Inc. logo
COOCooperVision — Research and development expense
$22.1M-13.7%
Hexcel logo
HXLComposite Materials — Research And Development Expense
$16.2M+37.3%
BioCryst Pharmaceuticals logo
BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)
$3.97M+30.4%
Cytokinetics logo
CYTKR&D
$95.53M-2.8%
Mineralys Therapeutics, Inc. logo
MLYSCapitalized research and development costs
$39.94M-11.2%
Amneal Pharmaceuticals, Inc. logo
AMRXSpecialty — Research And Development Expense
$5.1M-43.7%

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%
Enterprise value$1.81B+13.8%
P/S5.9×+0.5×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's compounding — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's compounding — research and development expense?
Harrow (HROW) reported compounding — research and development expense of $210K in Q1 2026.
How has Harrow's compounding — research and development expense changed year-over-year?
Harrow's compounding — research and development expense decreased by 6.3% year-over-year, from $224K to $210K.
What does compounding — research and development expense mean?
This metric tracks the expenditures dedicated to the discovery, formulation, and clinical evaluation of new or improved compounded ophthalmic products. It represents the company's commitment to innovation and long-term product pipeline development within the compounding segment. High levels of investment here are typically indicative of a strategy focused on future market expansion and competitive differentiation.